Tradestie Institutional Equity Comparison Engine

CRSP vs ACLX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin while ACLX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus ACLX at 61.7x Forward P/E and -3850.2% operating margin (-89.2% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ACLX sits in UNCLASSIFIED (1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs ACLX 61.7x Fwd P/E
Growth & Margin Winner CRSP
Op Margin -2058.6% vs -3850.2% ยท YoY +1325.1% vs -89.2%
Momentum & Technical Winner ACLX
1Y -20.5% vs +79.9% ยท 52W Pos 1% vs 100%
Options & Structure Winner ACLX
BREAKDOWN (52nd %ile IV) vs UNCLASSIFIED (1st %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
ACLX NASDAQ
Arcellx, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$115.07
+0.03% 1D
Market Cap $6.7B
1M Return +0.39%
1Y Return +79.88%
Forward P/E 61.7x
Unified AI Score
61.7 / 100 BUY
Tech 40.0 Fund 50.0 Flow 60.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% ACLX +79.88% Spread: +31.86 pp (ACLX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRSP TTM Op. Margin: -2058.6% ACLX TTM Op. Margin: -3850.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRSP vs ACLX. Trailing 12-month operating profitability (CRSP -2058.6% vs ACLX -3850.2%) and valuation multiples (CRSP 23.4x vs ACLX 61.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (5) vs ACLX (4)
Institutional Metric CRSP ACLX Criterion Row Winner
Market Capitalization Scale $4.1B $6.7B Larger Scale ACLX
Trailing P/E Ratio Valuation 23.4x 61.7x Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x 61.7x Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% -89.2% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -3850.2% Higher Margin CRSP
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -25.6% -53.4% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 100% ($48โ€“$115) Stronger Trend ACLX
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol -0.83ฮฒ ยท 1% Vol Lower Realized Risk ACLX
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 61.7 / 100 (BUY) Higher Composite ACLX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs ACLX Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACLX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live ACLX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor ACLX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.